Transplant Institute, University of Chicago, Chicago, IL.
Kovler Transplant Institute, Northwestern Memorial Hospital, Chicago, IL.
Transplantation. 2018 May;102(5):727-743. doi: 10.1097/TP.0000000000002147.
Effective immunosupression management is central to achieving optimal outcomes in liver transplant recipients. Current immunosuppression regimens and agents are highly effective in minimizing graft loss due to acute and chronic rejection but can also produce a substantial array of toxicities. The utilization of immunosuppression varies widely, contributing to the wide disparities in posttransplant outcomes reported between transplant centers. The International Liver Transplantation Society (ILTS) convened a consensus conference, comprised of a global panel of expert hepatologists, transplant surgeons, nephrologists, and pharmacologists to review the literature and experience pertaining to immunosuppression management to develop guidelines on key aspects of immunosuppression. The consensus findings and recommendations of the ILTS Consensus guidelines on immunosuppression in liver transplant recipients are presented in this article.
有效的免疫抑制管理是实现肝移植受者最佳结局的核心。目前的免疫抑制方案和药物在最大限度地减少因急性和慢性排斥反应导致的移植物丢失方面非常有效,但也会产生大量的毒性。免疫抑制的应用差异很大,这导致了不同移植中心报告的移植后结局存在很大差异。国际肝脏移植学会(ILTS)召集了一次共识会议,由全球一组专家级的肝病学家、移植外科医生、肾病学家和药理学家组成,以审查与免疫抑制管理相关的文献和经验,制定关于免疫抑制的关键方面的指南。本文介绍了 ILTS 共识指南关于肝移植受者免疫抑制的共识结果和建议。